<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927807</url>
  </required_header>
  <id_info>
    <org_study_id>misoprostol in induction</org_study_id>
    <nct_id>NCT03927807</nct_id>
  </id_info>
  <brief_title>Oral Misoprostol Solution in Labor Induction</brief_title>
  <official_title>A Comparison of the Efficacy and Safety of Repetitive Hourly Dose of Oral Misoprostol and Two Hourly Dose Oral Regimens for Cervical Ripening and Labor Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares safety and efficacy between repetitive hourly dose of oral misoprostol
      and two hourly dose oral regimens for cervical ripening and labor induction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Misoprostol is an effective agent for the induction of labor.existing guidelines recommend
      oral misoprostol solution every two hours.However,more research is required to optimize the
      use of oral misoprostol solution for labor induction.The current study is to compare efficacy
      and safety of repetitive hourly dose of oral misoprostol solution with two hourly dose of
      oral misoprostol solution for cervical ripening and labor induction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">January 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>24 hours from the first dose of induction till delivery</time_frame>
    <description>Successful vaginal delivery within 24 hours from starting induction of labor or cesarean section delivery after failed trial of induction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse maternal outcomes</measure>
    <time_frame>in 24 hours</time_frame>
    <description>As uterine hyper stimulation,fever,vomiting,shivering,nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse neonatal outcomes</measure>
    <time_frame>24 hours post partum</time_frame>
    <description>As neonatal intensive care unit admission,non reassuring fetal heart rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Labour,Induced</condition>
  <arm_group>
    <arm_group_label>repetitive hourly dose of oral misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose will be 10 microgram oral misoprostol that will be administered hourly up to 12 doses or till onset of regular uterine activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>two hourly dose of oral misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose will be 20 microgram oral misoprostol solution that will be administered every 2 hours up to 6 doses or till onset of regular uterine activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.
Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.
Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity.</description>
    <arm_group_label>repetitive hourly dose of oral misoprostol</arm_group_label>
    <arm_group_label>two hourly dose of oral misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparas

          -  Term pregnancy(equal or more than 37 wks)

          -  Bishop score &lt;6

          -  Cephalic presentation

          -  reassuring fetal heart rate pattern

          -  Not in labor ( no uterine contractions)

          -  Clinically adequate pelvis

          -  Singleton live pregnancy

        Exclusion Criteria:

          -  Allergic to misoprostol or prostaglandin analogues

          -  Previous uterine scar( cesarean section,hysterotomy,myomectomy)

          -  Multiple fetal gestations

          -  Fetal demise

          -  Preterm labor

          -  Malpresentations

          -  Non reactive cardiotocography at admission

          -  Cephalo pelvic disproportion

          -  Fetal macrosomia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>150 pregnant women who fulfill inclusion criteria.these will be subjected to history taking,physical examination,counseling and signing a written consent will be taken from each case.</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>essam sa hagag, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>essam sa hagag, MBBCh</last_name>
    <phone>01066813830</phone>
    <email>essamhagag742@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Cairo Governorate</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>esam sa hagag, MBBCh</last_name>
      <phone>01066813830</phone>
      <email>essamhagag742@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>27986461</citation>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Esam salah mohamed hagag</investigator_full_name>
    <investigator_title>Director,clinical research</investigator_title>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independent review panel.requestors will be required to sign a data access agreement.</ipd_access_criteria>
    <ipd_url>http://bethesda.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

